Targets › NT5E
10 programs from 8 companies in 26 trials: 13 Phase 1, 11 Phase 2, 2 Phase 3; Oncology; next expected readout Nov 2026.
Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, with AMP being the preferred substrate. Shows a preference for ribonucleotide monophosphates over their equivalent deoxyribose forms. (UniProt, P21589)
Open in Phaseline: the race on NT5E, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Oleclumab 5'-nucleotidase inhibitor | NT5E | Phase 3 | Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Triple Negative Breast Neoplasms … | Jan 2027 |
| Arcus Biosciences | Quemliclustat CD73 inhibitor | NT5E | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma; Gastrointestinal Tract Malignancies; Oligometastatic Prostate Cancer; Biliary Tract Carcinoma … | Nov 2030 |
| Bruno Bockorny | AGEN1423 Anti-CD73-TGFβ-Trap bifunctional antibody | NT5E, TGFB1 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Apr 2027 |
| AstraZeneca | Oleclumab 5'-nucleotidase inhibitor | NT5E | Phase 1 | Carcinoma, Non-Small-Cell Lung; Metastatic Microsatellite-stable Colorectal Cancer | Nov 2026 |
| Jonsson Comprehensive Cancer Center | Quemliclustat Adenosine pathway inhibitor; blocks adenosine production | NT5E | Phase 1 | Borderline Resectable Pancreatic Adenocarcinoma | Dec 2026 |
| Akeso | AK119 anti-CD73 monoclonal antibody | NT5E | Phase 1 | Colorectal Cancer; Solid Tumor, Adult | Dec 2026 |
| Institut Paoli-Calmettes | IPH5301 Anti-CD73 monoclonal antibody | NT5E | Phase 1 | Metastatic Cancer | Mar 2027 |
| Servier Bio-Innovation | S095024 Anti-CD73 antibody | NT5E | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Apr 2027 |
| Phanes Therapeutics | Mavrostobart (PT199) anti-CD73 monoclonal antibody | NT5E | Phase 1 | Non Small Cell Lung Cancer | Dec 2027 |
| Akeso | AK131 anti-PD-1 and CD73 bispecific antibody | PDCD1, NT5E | Phase 1 | Solid Tumor | Dec 2028 |
Pancreatic Ductal Adenocarcinoma (2) Non-Small Cell Lung Cancer (2) Borderline Resectable Pancreatic Adenocarcinoma (2) Metastatic Pancreatic Ductal Adenocarcinoma (1) Gastrointestinal Tract Malignancies (1) Oligometastatic Prostate Cancer (1) Biliary Tract Carcinoma (1) Locally Advanced Bladder Urothelial Carcinoma (1) Non-small Cell Lung Cancer (1) Metastatic Non-Small Cell Lung Cancer (NSCLC) (1) Triple Negative Breast Neoplasms (1) Metastatic Angiosarcoma (1)
mixed (6), small molecule (3)
AstraZeneca (2) Akeso (2) Arcus Biosciences (1) Bruno Bockorny (1) Phanes Therapeutics (1) Jonsson Comprehensive Cancer Center (1) Servier Bio-Innovation (1) Institut Paoli-Calmettes (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.